Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnteoTechASX:ADO -4.76% EV-to-EBIT is -8.04 as of Jul. 31, 2026. The stock has 4 warning signs investors should review. Among 1,241 Chemicals companies, AnteoTech ranks worse than 80580.1% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AnteoTech's Enterprise Value for the quarter that ended in Dec. 2025 was A$60.20 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AnteoTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-8.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnteoTech EV-to-EBIT Related Terms
AnteoTech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AnteoTech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, AnteoTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnteoTech EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, AnteoTech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AnteoTech's EV-to-EBIT falls into.
AnteoTech's current Enterprise Value is A$68.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AnteoTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-8.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnteoTech (ASX:ADO) has a EV-to-EBIT of -8.04 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AnteoTech and its competitors. According to the industry distribution chart, AnteoTech ranks #999999 out of 1241 companies in the Chemicals industry.
Is AnteoTech's EV-to-EBIT too high?
AnteoTech's current EV-to-EBIT is -8.04. Based on the distribution chart, AnteoTech ranks #999999 out of 1241 companies in the Chemicals industry, which is in the bottom quartile relative to peers.
How does AnteoTech's EV-to-EBIT compare to LIN and SHW?
According to the Chemicals industry distribution chart, AnteoTech ranks #999999 out of 1241 companies for EV-to-EBIT. This places AnteoTech in the lower half of its industry. The industry median EV-to-EBIT is 16.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 16.86, based on 1,241 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AnteoTech and its competitors. For the Chemicals industry, the median EV-to-EBIT is 16.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnteoTech's current EV-to-EBIT is -8.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnteoTech stock overvalued right now?
AnteoTech (ASX:ADO) has a current EV-to-EBIT of -8.04. The current EV-to-EBIT is -8.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AnteoTech (ASX:ADO), the current EV-to-EBIT is -8.04 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ADO has been successfully added to your 
